Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
HLA Typing for Transplant Market
The global HLA Typing for Transplant market is projected to expand from USD 1.96 billion in 2025 to USD 4.32 billion by 2035 at a compound annual growth rate (CAGR) of 8.2%. This growth is driven by increasing demand for precise donor-recipient matching in hematopoietic stem cell and solid organ transplants, technological advancements in molecular assays, and rising prevalence of chronic diseases necessitating transplantation. The market is segmented by product into reagents and consumables and software and services, and by technology into non-molecular and molecular assays.
End users include hospitals, diagnostic laboratories, and academic and research institutes, with applications spanning research and diagnostic purposes. North America currently leads the market, while Asia-Pacific is expected to exhibit the fastest growth over the forecast period.
Market size
Growth trajectory through 2035
HLA Typing for Transplant Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01 NGS-based HLA typing adoption
- Next-generation sequencing (NGS) has gained traction for high-resolution HLA typing, enabling better donor-recipient matching and reducing the risk of graft rejection.
-
Development 02 AI-driven HLA data interpretation
- Companies are integrating artificial intelligence and machine learning to improve the accuracy and speed of HLA typing data analysis, supporting clinical decision-making.
-
Development 03 Portable HLA typing devices
- The development of point-of-care HLA typing solutions is enhancing accessibility in resource-limited settings, enabling timely and accurate typing.
-
Development 04 Regulatory approvals and certifications
- Recent approvals for HLA typing assays and platforms have strengthened market confidence and accelerated adoption in transplant programs.
Emerging opportunities added
- Expansion in emerging markets Rapid healthcare infrastructure development and increasing healthcare expenditure in Asia-Pacific, Latin America, and the Middle East & Africa present significant growth opportunities for HLA typing solutions.
- Integration with digital health platforms The convergence of HLA typing with electronic health records (EHRs) and AI-driven analytics can enhance data interoperability, predictive modeling, and clinical decision support, unlocking new value propositions.
- Development of point-of-care HLA typing devices Portable and rapid HLA typing solutions can improve accessibility in remote or resource-limited settings, enabling timely and accurate donor-recipient matching.
- Collaborations and partnerships Strategic alliances between diagnostic manufacturers, transplant centers, and research institutions can accelerate innovation, streamline workflows, and expand market reach.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $1.96 Bn
- CAGR
- 8.20%
- Expansion
- 2.2×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top end-user
- transplant evaluation, post
- Top-5 concentration
- Low · ~35%
Forces at play
▲ top tailwind
- ▼ headwind
- High cost of advanced HLA typing technologies
- Named players
- 22 profiled
- Growth peak
- 2027–2031
Latest development
NGS-based HLA typing adoption: Next-generation sequencing (NGS) has gained traction for high-resolution HLA typing, enabling better donor-recipient matching and reducing the risk of graft rejection
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 152-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the HLA Typing for Transplant Market today ($1.96 Bn base), and how fast will it grow at 8.2% CAGR through 2035?
- Which of making holds the largest share, and how do the growth rates diverge?
- How is demand distributed across transplant screening, donor selection, and post, transplant monitoring to prevent graft rejection and complications, chart applications, and which application is scaling fastest?
- How do NORTH AMERICA compare on market share, growth rate, and regulatory posture?
- Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 19 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Increasing transplant volumes) and top restraints (led by High cost of advanced HLA typing technologies), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Increasing transplant volumes The rising incidence of end-stage organ failure and hematologic malignancies has driven demand for HLA typing to ensure optimal donor-recipient matching, reducing graft rejection and improving transplant outcomes.
- Technological advancements in molecular assays Innovations in next-generation sequencing (NGS) and real-time PCR have enhanced the accuracy, speed, and resolution of HLA typing, enabling better clinical decision-making and expanding market adoption.
- Growth in personalized medicine The integration of HLA typing into precision medicine frameworks supports tailored therapeutic strategies, particularly in oncology and autoimmune disorders, fostering market expansion.
- Regulatory and accreditation requirements Stringent regulatory standards for transplant safety and quality are compelling healthcare providers to adopt advanced HLA typing solutions, reinforcing market growth.
Restraints
Holding it back
- High cost of advanced HLA typing technologies The capital expenditure and operational costs associated with molecular assays and NGS platforms limit adoption in resource-constrained settings, particularly in emerging markets.
- Complexity of HLA typing workflows The need for specialized expertise, stringent sample handling, and interpretation of high-resolution typing data poses operational challenges for laboratories and healthcare systems.
- Limited donor registries and matching efficiency Insufficient diversity in donor registries, particularly among minority populations, reduces the likelihood of finding suitable matches, constraining the overall efficacy of transplant programs.
- Reimbursement and insurance barriers Inconsistent coverage policies for advanced HLA typing procedures across geographies can delay adoption and limit market penetration.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Increasing transplant volumes | +3.7% | Global | 2025–2035 |
| Technological advancements in molecular assays | +2.3% | Global | 2025–2035 |
| Growth in personalized medicine | +1.8% | Global | 2025–2035 |
| Regulatory and accreditation requirements | +1.2% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High cost of advanced HLA typing technologies | −1.5% | Global | 2025–2029 |
| Complexity of HLA typing workflows | −1.0% | Global | 2025–2029 |
| Limited donor registries and matching efficiency | −0.7% | Global | 2025–2029 |
The HLA Typing for Transplant market is segmented by product, technology, end user, application, and region.
Revenue share by type · 2025 base year
% OF $1.96 BN HLA TYPING FOR TRANSPLANT MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $1.96 Bn HLA Typing for Transplant Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
making
By application
-
transplant screening, donor selection, and post
-
transplant monitoring to prevent graft rejection and complications
-
chart
-
template="hbar_divergent" data
-
palette="dual_tone_teal">
-
size="15" fill="#0f172a" text
-
anchor="middle" font
-
weight="bold">Regional Coverage
By technology
-
Molecular Assay:
-
dependent cytotoxicity (CDC) and flow cytometry
-
specific oligonucleotide (SSO), sequence
-
based typing (SBT), and next
-
generation sequencing (NGS) for high
-
resolution HLA typing
By end-user industry
-
transplant evaluation, post
-
transplant monitoring, and clinical decision
-
making
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $1.96 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~38.7% in 2025. Driven by manufacturing scale and end-market density.
Competitive landscape
Who's competing, and how
The market is Low concentration. 22 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The HLA Typing for Transplant market is moderately fragmented, with a mix of global diagnostic leaders, specialized biotechnology firms, and emerging players. Key companies focus on innovation, strategic partnerships, and geographic expansion to strengthen their market position.
Concentration snapshot
Top 5 players control 35.0% of the market
Aggregate 2025 share of the top 5 named players (real market share data). Individual company shares in the full report.
Competitive tiers
Players are bucketed by base-year market share: Leaders ≥ 7%, Challengers 3–7%, Emerging < 3%. Full tier rationale + revenue estimates in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Johnson & Johnson · Merck · Novartis
Tier 2 · Challengers
4companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Roche · AbbVie · Eli Lilly · AstraZeneca
Tier 3 · Emerging
15companies
Niche or early-stage, differentiated technology or early-mover positioning.
Thermo Fisher Scientific · Danaher Corporation · Roche Diagnostics · Abbott Diagnostics · Siemens Healthineers
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Thermo Fisher Scientific
Rank 01Share est. ~13%Revenue $■■■MHQ ■■■ -
Danaher Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Diagnostics
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Diagnostics
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Bio-Rad Laboratories
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
QIAGEN N.V
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Hologic Inc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 14 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• Who are the key players in the global HLA typing for transplant market?
Some key players operating in the global HLA typing for transplant market include Thermo Fisher Scientific Inc., Immucor Inc., Luminex Corporation, Qiagen N.V., Bio-Rad Laboratories Inc., Illumina Inc., Affymetrix Inc., F. Hoffmann-La Roche Limited, Genome Diagnostics B.V., Abbott Laboratories and Inc. -
• What are the factors driving the global HLA typing for transplant market?
The demand for organ transplants, such as kidney, liver, heart, and bone marrow, continues to rise due to factors like a growing aging population, an increase in chronic diseases, and advancements in surgical procedures. HLA typing is essential for matching donors with recipients to minimize the risk of organ rejection and improve transplant success rates. -
• How big is the global HLA typing for transplant market?
The global HLA typing for transplant market size was estimated at USD 741.96 million in 2021 and is expected to reach USD 1346.09 million in 2029. -
• What is the global HLA typing for transplant market growth?
The global HLA typing for transplant market is expected to grow at a compound annual growth rate of 7.73% from 2022 to 2029 to reach USD 1346.09 million by 2029. -
• Which region accounted for the largest global HLA typing for transplant market share?
The North America dominated the global HLA typing for transplant market with a share of 36% in 2021.
The HLA Typing for Transplant Market is projected to reach $4.31 Bn by 2035, up from $1.96 Bn in 2025 — a 8.20% CAGR equating to roughly 2.2× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.